Figure - available from: Journal of Clinical Medicine
This content is subject to copyright.
Effect of co-administration of PARP inhibitors with anticancer agents on grade ≥ 3 cardiac adverse events.
Source publication
Objective: This study aimed to assess the potential of PARP inhibitors to prevent cardiotoxicity. Methods: First, a re-analysis and update of a previously published study was conducted. Additional searches were conducted of the PubMed and Cochrane Central Register of Controlled Trials databases on 2 June 2023. After the selection process, the poole...
Similar publications
The current focus of ovarian cancer (OC) research is the improvement of treatment options through maximising drug effectiveness. OC remains the fifth leading cause of cancer-induced mortality in women worldwide. In recent years, nanotechnology has revolutionised drug delivery systems. Nanoparticles may be utilised as carriers in gene therapy or to...
The application of PARP inhibitors has revolutionized cancer treatment and has achieved significant advancements, particularly with regard to tumors with defects in genes involved in homologous recombination repair (HRR) processes, such as BRCA1 and BRCA2. Despite the promising outcomes of PARP inhibitors, certain limitations and challenges still e...
Background: As the treatment landscape for advanced ovarian cancer (OC) evolves, it is important to understand patient outcomes in real-world clinical practice. OCRWE-Finland was an observational cohort study investigating OC outcomes, including treatment patterns, time to next treatment 1 (TTNT1), overall survival and healthcare resource utilisati...
Poly (ADP‐ribose) Polymerase inhibitors (PARPi) have demonstrated remarkable clinical efficacy in treating ovarian cancer (OV) with BRCA1/2 mutations. However, drug resistance inevitably limits their clinical applications and there is an urgent need for improved therapeutic strategies to enhance the clinical utility of PARPi, such as Olaparib. Here...
BReast CAncer gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) encode for tumor suppressor proteins which are critical regulators of the homologous recombination (HR) pathway, the most precise and important DNA damage response mechanism. Dysfunctional HR proteins cannot repair double-stranded DNA breaks in mammalian cells, a situation called HR defi...
Citations
... However, niraparib demonstrates an increased risk of hypertension and atrial flutter, which necessitates close monitoring of blood pressure and heart rhythm disturbances during treatment. When combined with antiandrogens, the risk of cardiac AEs increases; however, these agents are also associated with decreased cardiac AEs when administered in combination with chemotherapy/bevacizumab [23]. While having some cardioprotective effect, other studies have shown these drugs to be linked to major adverse cardiac events, with an incidence of 17.5% for hypertension [24]. ...
Background/Objectives: Several drugs used to treat prostate cancer have been reported to cause cardiovascular adverse events, and this study sought to identify the real-world risk. Methods: This study utilized real-world data from the FAERS to analyze the association between prostate cancer treatment and cardiovascular adverse events. It evaluated men treated with LHRH agonists and antagonists, antiandrogens, androgen synthesis inhibitors, and PARP inhibitors from 2003 to 2023. This study included patients treated with leuprolide, goserelin, triptorelin, degarelix, relugolix, bicalutamide, flutamide, apalutamide, nilutamide, abiraterone, enzalutamide, olaparib, rucaparib, talazoparib, and niraparib. The main outcome measure was the reported odds ratio (ROR) of adverse cardiovascular event associated with these treatments. Results: Among the 4,049,329 unique adverse event reports, 4391 cardiovascular events were identified. Leuprolide (ROR 0.481, 95% CI: 0.423-0.547), triptorelin (ROR 0.527, 95% CI: 0.305-0.909), enzalutamide (ROR 0.393, 95% CI: 0.341-0.452), and olaparib (ROR 0.145, 95% CI: 0.054-0.386) reduced the risk of myocardial infarction. Goserelin increased the risk of myocardial infarction (ROR 2.235, 95% CI: 1.367-3.654). Degarelix and relugolix both increased the risk of heart failure (ROR 3.136, 95% CI: 2.186-4.497), and enzalutamide was associated with an increased risk of heart failure (ROR 1.305, 95% CI: 1.135-1.501). Bicalutamide increased the risk of unstable angina (ROR 3.019, 95% CI: 1.621-5.622) and heart failure (ROR 3.730, 95% CI: 3.085-4.510). Niraparib increased the risk of hypertension (ROR 4.154, 95% CI: 1.709-10.092). Conclusions: These findings underscore the need for clinicians to monitor cardiac complications in patients undergoing these therapies.
